Summary of Key Points Core Viewpoint - The company has completed the investment project "Annual Production of 1,000kg Antibody Industrialization Construction Project" and plans to permanently supplement its working capital with the remaining raised funds, which aligns with its operational needs and long-term development strategy [9][10]. Fundraising Basic Information - The total amount raised by the company was RMB 3,476,520,000, with a net amount of RMB 3,303,432,172.40, all of which was received by January 10, 2022 [1][2]. Fund Management and Usage - The company established special accounts for managing the raised funds, which are stored in accounts approved by the board of directors, ensuring investor protection [2]. - As of February 28, 2025, the remaining balance of the raised funds for the "Annual Production of 1,000kg Antibody Industrialization Construction Project" was RMB 29,204,764.93 [4][6]. Project Completion and Fund Surplus - The project has been completed as of December 31, 2024, and the remaining funds will be used to enhance operational efficiency [6][9]. - The surplus funds amounting to RMB 18,944.20 million will be permanently added to the working capital [10]. Reasons for Fund Surplus - The surplus was primarily due to prudent fund management, effective cost control, and the use of self-owned funds and bank loans for project expenses, leading to a certain amount of surplus [7][9]. Future Fund Usage Plan - The company plans to use the surplus funds to support daily operations, ensuring efficient use of the raised funds [8][10]. Review and Approval Process - The decision to conclude the investment project and reallocate surplus funds has been approved by the board of directors and the supervisory board, and will be submitted for shareholder meeting approval [10][11].

海通证券股份有限公司 关于峰岹科技（深圳）股份有限公司 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为峰岹 科技（深圳）股份有限公司（以下简称"峰岹科技"或"公司"）首次公开发行 股票并在科创板上市的持续督导保荐机构，根据《证券发行上市保荐业务管理办 法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等相关规定，对峰岹科技 2024 年度募集资金存 放与实际使用情况的事项进行了核查，具体情况及核查意见如下： 一、募集资金基本情况 （一） 实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意峰岹科技（深圳）股份有限公司首次 公开发行股票注册的批复》（证监许可2022457 号）并经上海证券交易所同意， 公司首次向社会公众公开发行人民币普通股（A 股）2,309.0850 万股，发行价格 为人民币 82 元/股，募集资金总额为人民币 189,344.97 万元，扣除发行费用合计 人民币 16,498.79 万元（不含增值税）后，实际募集资金净额为人民币 1 ...

Group 1 - The merger between Guotai Junan and Haitong Securities has been announced, resulting in the new company name "Guotai Haitong Securities Co., Ltd." and the new stock abbreviation "Guotai Haitong" [1] - The simulated combined company is projected to have total assets of 1.73 trillion yuan and a net asset attributable to the parent company of 328.3 billion yuan by the end of 2024, leading the industry in capital strength [1] - The brokerage business net income from commissions is reported at 11.822 billion yuan, ranking first in the industry, while the investment banking business net income from commissions is 4.603 billion yuan, also leading the industry [1] Group 2 - Haitong Securities has announced a projected loss for 2024, primarily due to a significant decline in the valuation of overseas financial assets, resulting in reduced investment income and changes in fair value [1] - Guotai Junan plans to distribute cash dividends to shareholders twice in 2024, totaling approximately 6.258 billion yuan, which represents 48.05% of the net profit attributable to the parent company, marking a historical high for the company [1] - The interim cash dividend is set at 1.5 yuan per 10 shares, with a proposed year-end dividend of 2.8 yuan per 10 shares, continuing the high dividend policy of both companies post-merger [1] Group 3 - In the 2024 annual report, Guotai Junan reported an operating income of 43.397 billion yuan, reflecting a year-on-year growth of 20.08%, and a net profit attributable to the parent company of 12.44 billion yuan, which is a 42.7% increase year-on-year [3]

Core Viewpoint - Guotai Junan reported significant growth in its 2024 annual performance, with a notable increase in revenue and net profit, reflecting the company's strong operational capabilities and strategic initiatives [1][2]. Financial Performance - The company achieved operating revenue of 43.397 billion yuan, a year-on-year increase of 20.08% [2] - Net profit attributable to shareholders reached 13.024 billion yuan, up 38.94% year-on-year [2] - Basic earnings per share were 1.39 yuan, representing a growth of 41.84% [2] - The weighted average return on equity was 8.14%, an increase of 2.12 percentage points [2] - Total assets surpassed 1 trillion yuan, reaching 1.047745 trillion yuan, a growth of 13.22% [2] Business Segments - Wealth management transformation was emphasized, with the number of users on the Junhong APP reaching 41.6397 million, a 3.0% increase from the previous year [2] - The number of personal fund accounts grew by 8.3% to 19.3194 million [2] - The company maintained a market share of 9.63% in the investment banking sector, ranking third in the industry [2] Strategic Initiatives - The company is focusing on enhancing three capabilities: improving retail customer service through investment advisory teams, increasing business synergy, and emphasizing strategic and long-term value investments [3][4] - Guotai Junan is actively embracing digital transformation, having established an enterprise-level database and upgraded its management dashboard [4] - The company is advancing its international strategy and optimizing its international business structure [4] Mergers and Acquisitions - Guotai Junan announced a merger with Haitong Securities, with the combined total assets projected to reach 1.73 trillion yuan and net assets of 328.3 billion yuan [5] - The merger positions the company as the industry leader in capital strength and brokerage business net income [5] Dividend Distribution - The company plans to distribute cash dividends twice in 2024, totaling approximately 6.258 billion yuan, which is 48.05% of the net profit attributable to shareholders, marking a historical high for the company [6]

Core Viewpoint - The company has decided to postpone the implementation timeline of its aviation core components intelligent manufacturing project due to various factors, including international export restrictions and the need for equipment adjustments to meet customer requirements [1][5][7] Fundraising Overview - The company raised a total of RMB 252.26 million through its initial public offering, with a net amount of RMB 252.26 million after deducting issuance costs [1][2] - The fundraising was approved by the China Securities Regulatory Commission on March 23, 2021, allowing the issuance of 27.97 million shares at a price of RMB 9.02 per share [1] Project Status and Changes - As of March 28, 2025, the total investment amount for the aviation core components intelligent manufacturing project is expected to reach RMB 205.44 million, with an actual investment of RMB 200.14 million [2][3] - The project has undergone changes in its implementation location and subject, moving from Suzhou to Nanjing and then to Zhengzhou, to optimize resource allocation and enhance production efficiency [3][4] Reasons for Delay - The delay is attributed to stricter export controls on high-end CNC machine tools, which have extended the import approval process and complicated equipment acquisition [5][6] - Adjustments to equipment specifications and parameters to better align with customer needs have also contributed to the extended timeline [5][6] Impact of Delay - The postponement of the project timeline does not affect the total investment amount, investment purpose, or construction scale, ensuring that shareholder interests remain protected [5][6] - The company plans to extend the expected usable status of the project to March 2025, with a focus on maintaining project quality and compliance with regulatory requirements [4][5] Approval Process - The board of directors and the supervisory board have approved the project delay, confirming that it aligns with the company's development strategy and does not adversely affect project implementation [6][7] - The supervisory board has expressed that the decision is prudent and complies with relevant regulations, ensuring no harm to the company's or shareholders' interests [6][7]

Core Viewpoint - The company, Hefei Taihe Intelligent Technology Group Co., Ltd., has successfully completed its initial public offering (IPO) and subsequent private placement of shares, with ongoing supervision by designated securities firms to ensure compliance with regulatory requirements [1][3]. Group 1: Initial Public Offering - The company issued 18.99 million shares at a price of RMB 21.91 per share, raising a total of RMB 416.07 million, with a net amount of RMB 41.61 million after deducting issuance costs [1]. - The continuous supervision of the IPO process was initially handled by Dongfang Citic Securities, which will now be succeeded by Haitong Securities due to the company's new private placement [2]. Group 2: Private Placement - The company has received approval for a private placement, raising a total of RMB 350.58 million, with a net amount of RMB 344.49 million after deducting issuance costs [3]. - The private placement shares were listed on the Shanghai Stock Exchange on March 15, 2023, with Haitong Securities acting as the continuous supervising sponsor [3]. Group 3: Continuous Supervision and Compliance - Haitong Securities will oversee the company from March 15, 2023, to December 31, 2024, ensuring compliance with relevant regulations and guidelines [3]. - The company has established a governance structure that meets the requirements for listed companies, with effective execution of its articles of association and meeting procedures [5]. - The company has a complete information disclosure system, fulfilling necessary disclosure obligations without any false statements or omissions [6]. Group 4: Financial and Operational Stability - The company has maintained stable operational conditions, with no significant changes in its business model or market environment [7]. - The company has established a management system for the use of raised funds, ensuring compliance with decision-making procedures and information disclosure [6][7].

Group 1 - Bid Pharma's stock closed at 47.98 yuan, with a decline of 11.15%, resulting in a total market capitalization of 4.361 billion yuan, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 11, 2022, with an issuance of 16.2291 million shares at a price of 88.00 yuan per share [1] - The total amount raised from the issuance was 1.428 billion yuan, with a net amount of 1.309 billion yuan after deducting issuance costs, exceeding the original plan by 874.6428 million yuan [1] Group 2 - The strategic placement of Bid Pharma's issuance involved participation from the underwriting institution's subsidiaries and a special asset management plan for senior management and core employees [2] - The underwriting institution, Haitong Securities, participated in the strategic placement, acquiring 4.00% of the public offering, amounting to 649,164 shares valued at approximately 57.13 million yuan [2] - The annual profit distribution announced on May 19, 2023, indicated a cash dividend of 1.54 yuan per share and a capital reserve increase of 0.4 shares per share, resulting in a total distribution of approximately 99.97 million yuan and an increase of 25.97 million shares [2]

Core Viewpoint - The report highlights a significant decline in revenue and net profit for Huahong Semiconductor, attributed to weak demand in automotive, industrial, and new energy sectors, as well as intense market competition affecting sales prices [2][9]. Financial Performance - Revenue for 2024 is reported at 1,438,830.77 million RMB, a decrease of 11.36% compared to the previous year [17]. - Net profit attributable to shareholders decreased by 80.34%, while net profit excluding non-recurring gains and losses fell by 84.80% [2][17]. - Basic earnings per share dropped by 83.21% to 0.22 RMB, and diluted earnings per share decreased by 83.08% to 0.22 RMB [17][18]. - Total assets increased by 15.36% to 8,793,523.15 million RMB [17]. Operational Overview - The company is under continuous supervision by Guotai Junan Securities and Haitong Securities, with a focus on compliance with relevant regulations and effective governance [4][7]. - No major violations or issues requiring rectification were reported during the supervision period [9][17]. Market and Industry Risks - The semiconductor industry faces cyclical demand fluctuations, with potential risks from economic slowdowns and increased competition [10][12]. - The company must continuously innovate and upgrade its technology to maintain competitiveness in a rapidly evolving market [10][12]. - Risks related to supply chain disruptions, particularly from geopolitical tensions affecting key suppliers, could impact production and operational stability [11][14]. Research and Development - The company has focused on enhancing its core competencies in specialized process technologies, with a total of 4,644 patents granted as of December 2024 [18][19]. - R&D efforts are concentrated on differentiated technologies, including embedded non-volatile memory and power devices, to meet market demands [19][20]. Fund Utilization - As of December 31, 2024, the company reported a balance of 696,643.96 million RMB in its fundraising account, with all funds utilized in compliance with regulatory requirements [21][22].

Core Viewpoint - The report outlines the fundraising and usage status of Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. for the year 2024, confirming compliance with regulatory requirements and detailing the management of raised funds [1][6][7]. Fundraising Overview - The company raised a total of RMB 1,074 million through the issuance of 12 million shares at RMB 8.95 per share, with net proceeds amounting to RMB 974.32 million after deducting issuance costs of RMB 99.68 million [1][3]. - As of December 31, 2024, the total amount used from the raised funds was RMB 486.36 million, with an additional RMB 346.45 million from over-raised funds permanently supplementing working capital [1][3]. Fund Usage and Management - The company utilized RMB 15.24 million of the raised funds during the reporting period and had a remaining balance of RMB 193.10 million in the dedicated account as of December 31, 2024 [1][3]. - A three-party supervision agreement was signed with banks to ensure proper management of the raised funds, and the company has adhered to its internal management procedures [1][4]. Cash Management - The company approved the use of up to RMB 250 million of temporarily idle raised funds for cash management, focusing on safe and liquid investment products [4][8]. - The company engaged in structured deposits and achieved returns from these investments, with no remaining balance in investment products as of the end of the reporting period [5][8]. Compliance and Audit - The report confirms that the company has complied with all relevant regulations regarding the management and usage of raised funds, with no violations reported [6][7]. - The auditing firm PwC provided a verification report affirming that the fundraising and usage report accurately reflects the company's financial activities [6][7].

Group 1 - The stock price of Suochen Technology (688507.SH) fell by 5.76% to 82.92 yuan as of the market close on March 27, 2023, indicating that the stock is currently in a state of decline since its IPO [1] - Suochen Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 18, 2023, with an issuance of 10,333,400 shares at a price of 245.56 yuan per share, resulting in a total fundraising amount of 253,746.97 million yuan [1] - The net fundraising amount was 231,574.91 million yuan, exceeding the original plan by 134,684.55 million yuan, with the funds allocated for various projects including R&D center construction and marketing network development [1] Group 2 - The company announced a profit distribution plan on June 13, 2023, distributing a cash dividend of 0.15 yuan per share and a capital reserve increase of 0.48 shares for every share held, resulting in a total cash dividend of 6,200,010 yuan and an increase of 19,840,032 shares [2] - The total share capital after the distribution will be 61,173,432 shares, with the ex-dividend date set for June 20, 2023 [2] - For the 2023 annual profit distribution, the company plans to distribute a cash dividend of 3.80 yuan for every 10 shares and a capital reserve increase of 4.60 shares for every 10 shares, with the ex-dividend date set for June 19, 2024 [2]